Hearing company Decibel Therapeutics nabs $52 mln Series A

By Iris Dorbian — 4 months ago

Cambridge, Massachusetts-based hearing company Decibel Therapeutics has launched with $52 million in Series A funding. Third Rock Ventures LLC led the round with participation from SR One. In addition to the funding, Kevin Starr, chairman and interim CEO of Decibel Therapeutics, Craig Muir, partner and chief technology officer at Third Rock and Dr. Jens Eckstein, president of SR One, have been named to Decibel Therapeutics’ board of directors.

Continue

Neon Therapeutics inks $55 mln Series A

By Iris Dorbian — 4 months ago

Neon Therapeutics has launched with $55 million in Series A funding. Third Rock Ventures led the round with participation from Clal Biotechnology Industries and Access Industries. Based in Cambridge, Massachusetts, Neon Therapeutics is an immuno-oncology company focused on treating cancer.

Continue

Rhythm Metabolic racks up $40 mln Series A

By Iris Dorbian — 6 months ago

Boston-based Rhythm Metabolic, a subsidiary of Rhythm, has closed $40 million in Series A funding. The investors included OrbiMed, Deerfield Management, Wellington Management Company, MPM Capital, New Enterprise Associates, Third Rock Ventures, Pfizer Ventures and Ipsen. In conjunction with the funding, Jonathan Silverstein of OrbiMed has been appointed to Rhythm Metabolic’s board of directors. Rhythm Metabolic is focused on treating obesity caused by genetic deficiencies.

Continue

VC-backed Kala taps Iwicki as executive chairman

By Iris Dorbian — 9 months ago

Waltham, Massachusetts-based Kala Pharmaceuticals, a developer of treatments for ocular diseases, has named Mark Iwicki as executive chairman and a member of its board of directors. Previously, Iwicki was the president and CEO of Civitas Therapeutics Inc. Kala’s backers include Crown Venture Fund, Lux Capital, Polaris Partners, Third Rock Ventures and Ysios Capital.

Continue

CytomX grabs $20 mln Series C

By Iris Dorbian — 1 year ago

Biotech firm CytomX has received $20 million in Series C financing. Pfizer Venture Investments led the round with participation from previous backers Third Rock Ventures, Canaan Partners and the Roche Venture Fund. In addition to the funding, Dr. Elaine Jones, executive director of venture capital at Pfizer Venture Investments, has been added to CytomX’s board of directors. Her appointment becomes effective January 15, 2015.

Continue

Allena Pharma raises $25 mln

By Luisa Beltran — 1 year ago

Allena Pharmaceuticals has completed a $25 million Series B financing led by HBM Partners. Existing investors Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners and new investor Pharmstandard International also participated. Newton, Mass.-based Allena is specialty biopharmaceutical company that develops non-systemic protein therapeutics to treat metabolic and orphan diseases.

Continue

Blueprint Medicines ropes in $50 mln

By Iris Dorbian — 1 year ago

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.

Continue

VC-backed Rhythm files for IPO

By Iris Dorbian — 1 year ago

Rhythm has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Citigroup and Cowen and Company are serving as the lead underwriters. Based in Boston, Rhythm is a biopharmaceutical firm that focuses on treating metabolic disorders. Its backers include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen and Pfizer Ventures.

Continue

VC-backed Jounce Therapeutics names new CEO

By Iris Dorbian — 2 years ago

Jounce Therapeutics, which is backed by Third Rock Ventures, has hired Dr. Richard Murray as CEO. Murray is replacing interim CEO Dr. Cary Pfeffer, a partner at Third Rock Ventures, who will become chairman of Jounce’s board of directors. Previously, Murray worked at Merck where he recently served as senior vice president of biologics and vaccines research and was a member of the Merck Research Laboratories leadership team. Based in Cambridge, Mass., Jounce Therapeutics is focused on discovering and developing cancer immunotherapies.

Continue

DC Devices picks up $34 mln Series D

By Iris Dorbian — 2 years ago

DC Devices, a medical device firm focused on treating heart failure, has secured $34 million in Series D funding. Accelmed led the round with participation from investors that included Third Rock Ventures, General Catalyst Partners and Lumira Capital.

Continue

VC-backed Editas Medicine hires CEO

By Iris Dorbian — 2 years ago

Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners Innovation Fund.

Continue

VC-backed Solstice Biologics hires new president/CEO and CFO

By Iris Dorbian — 2 years ago

San Diego-based biotech startup Solstice Biologics, which is backed by venBio and Aeris Capital, has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm’s board of directors. Also, the firm has named John Borgeson as chief financial officer. Previously, Tartaglia worked at Third Rock Ventures where he was a partner while Borgeson was vice president of finance for Pfizer‘s biotherapeutic and bioinnovation center.

Continue